Monoclonal Antibody Therapies in Respiratory Syncytial Virus Prophylaxis-An Umbrella Review
- Ilari Kuitunen; Katri Backman; Eveliina Gärdström; Marjo Renko
Access Resources
About
This article reviews the use of monoclonal antibodies to prevent respiratory syncytial virus (RSV) in infants. It describes how RSV causes many hospitalizations and deaths in young children. Monoclonal antibodies like palivizumab and nirsevimab help reduce RSV-related hospital visits, especially in preterm babies. While these treatments are effective against infections, they don't lower death rates from RSV. The review highlights the need for more studies on real-world effectiveness and safety as new prevention methods emerge, including vaccines for pregnant women to protect newborns from RSV during their first months of life.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.